8-K: Equillium Announces Positive Topline Data from Phase 2 Alopecia Areata Study

Equillium's Phase 2 study of EQ101 in alopecia areata shows a favorable safety profile and improvements in hair loss, exceeding historical placebo response rates.

Summary

• Equillium, Inc. announced topline data from its Phase 2 study of EQ101 for alopecia areata, an autoimmune disease causing hair loss.
• The study evaluated the safety and efficacy of EQ101 using Severity of Alopecia Tool (SALT) scores, where 100 represents total hair loss and 0 represents no hair loss.
• The results showed a favorable safety profile with no serious adverse events.
• 20% of all subjects who completed 24 weeks of treatment (n=25) achieved a SALT score of 20 or less.
• Among subjects with moderate to severe alopecia areata (n=17), 29% achieved a SALT score of 20 or less by week 24, with a mean SALT improvement of 18%.
• EQ101 is a multi-cytokine inhibitor targeting IL-2, IL-9, and IL-15, which are key drivers of the disease.
• The study enrolled 36 subjects with a mean baseline SALT score of 76, and 25 completed the study.
• The majority of adverse events were Grade 1 or 2, with the most common being upper respiratory tract infection, headache, and fatigue.
• Two Grade 3 events, transient lymphocytopenia and fatigue, were considered related to the study treatment.
• Preliminary data also indicate reductions of cell surface CD132 on both CD8 and NK cells, suggesting target engagement.

Sentiment

Score: 7

Explanation: The document presents positive topline data with a favorable safety profile and efficacy signals, but there are some concerns about the dropout rate and the need for further studies. The sentiment is positive overall, but not overwhelmingly so.

Positives

• EQ101 showed a favorable safety profile with no serious adverse events in the Phase 2 study.
• The study demonstrated improvements in SALT scores, with 20% of all subjects and 29% of moderate to severe subjects achieving a score of 20 or less.
• EQ101's mechanism of action targets key cytokines involved in alopecia areata.
• The majority of adverse events were mild, indicating good tolerability.
• Preliminary data suggests the drug is engaging its target, as shown by reductions in CD132 on immune cells.

Negatives

• Eleven subjects discontinued the study early, although only five were due to adverse events.
• Two subjects experienced Grade 3 adverse events, including transient lymphocytopenia and fatigue.
• The study had a relatively high dropout rate, with 11 out of 36 subjects discontinuing early.

Risks

• The study had a dropout rate of 11 out of 36 subjects, which could impact the overall results.
• Two subjects experienced Grade 3 adverse events, which, while not serious, could raise concerns about the drug's safety profile.
• The study is a single-dose, proof-of-concept study, and further studies are needed to confirm these results and optimize dosing.
• The company is still in the process of developing a subcutaneous formulation, which may introduce additional risks and delays.

Future Outlook

The company plans to further develop EQ101, including dose optimization, transition to a subcutaneous formulation, and expansion into other indications such as vitiligo. Further clinical development in AA, and potential expansion indication(s), is planned during 2025.

Industry Context

The announcement is significant in the context of the medical dermatology market, where there is a large unmet need for safe and effective therapies for alopecia areata. Current treatments are primarily JAK inhibitors, which have safety concerns. EQ101 is positioned as a potentially safer alternative.

Comparison to Industry Standards

• The study results are compared to JAK inhibitors such as baricitinib, ritlecitinib and deuruxolitinib, which are currently approved for alopecia areata.
• The placebo response rates in the EQ101 study are consistent with the low placebo rates observed in other alopecia areata trials, averaging around 3.6%.
• The response rates for EQ101, particularly in moderate to severe patients, are comparable to the active arms of other Phase 2 and 3 studies of JAK inhibitors, which range from 11% to 33% for SALT 20 response rates.
• The mean SALT improvement from baseline of 18% in the moderate to severe group is within the range of 17% to 45% observed in Phase 3 studies of JAK inhibitors.
• The study highlights that patients with very severe disease (SALT >95) tend to have slower responses and may require increased dosing and longer treatment, which is consistent with findings from other studies.

Stakeholder Impact

• Shareholders will likely view the positive topline data favorably.
• Patients with alopecia areata may benefit from a new, potentially safer treatment option.
• The company's employees may be impacted by the need to advance the development of EQ101.
• The company's suppliers and creditors may be impacted by the company's future plans.

Next Steps

• The company will complete PK/PD characterization of EQ101.
• They will continue assessment with KOLs to finalize the AA development plan.
• The company will target a patient population, such as moderate to severe patients.
• They will optimize the dose of EQ101.
• The company will transition to a subcutaneous formulation.
• They will advance CMC activities of selected sub-cutaneous formulations to support the development plan.
• The company plans to initiate further clinical development in AA, and potential expansion indication(s), during 2025.

Key Dates

Keywords

Alopecia Areata, EQ101, Autoimmune Disease, Hair Loss, Clinical Trial, Cytokine Inhibitor, SALT Score, Phase 2 Study, Dermatology, IL-2, IL-9, IL-15